Fennec (FENC) CFO Robert Andrade Receives Award of 1,703 Shares

What Happened
Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals (FENC), had 1,703 shares released from restriction on September 30, 2026. The Form 4 reports this as an award/acquisition at $0.00 per share (total reported value $0). Footnote F1 says these shares were released from awards originally granted on 5/16/2024 and 3/28/2025.

Key Details

• Transaction date: 2026-09-30; Form 4 filed: 2026-10-01 (timely filing).
• Transaction type: Award/Release of restricted shares (code A).
• Shares acquired: 1,703 at $0.00; reported aggregate value $0.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: F1 — represents shares released from restriction from awards dated 5/16/2024 and 3/28/2025.
• No sale or cash purchase reported; no tax-withholding or 10b5-1 plan noted in the filing.

Context
This transaction reflects restricted shares vesting/release as part of prior awards, not an open-market purchase or sale. Such releases are common as part of executive compensation and do not, by themselves, indicate a change in insider sentiment about the stock.